Home > Insider Trading > Filing (0001140361-24-038772)

Filing Details

Accession Number:: 0001140361-24-038772
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-08-27 21:22:44
Reporting Period:: 2024-08-26

Accepted Time:: 2024-08-27 21:22:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1368514	Adma Biologics Inc.	ADMA	Biological Products, (No Disgnostic Substances) (2836)	562590442

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1542517	S Adam Grossman	C/O Adma Biologics, Inc. 465 State Route 17 Ramsey NJ 07446	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2024-08-26	64,405	$3.35	2,124,131	No	4	M	Direct
Common Stock	Acquisiton	2024-08-26	55,000	$5.00	2,179,131	No	4	M	Direct
Common Stock	Acquisiton	2024-08-26	16,984	$5.96	2,196,115	No	4	M	Direct
Common Stock	Acquisiton	2024-08-26	40,500	$9.37	2,236,615	No	4	M	Direct
Common Stock	Acquisiton	2024-08-26	60,000	$10.80	2,296,615	No	4	M	Direct
Common Stock	Disposition	2024-08-26	236,889	$17.69	2,059,726	No	4	S	Direct
Common Stock	Acquisiton	2024-08-27	341,960	$3.35	2,401,686	No	4	M	Direct
Common Stock	Acquisiton	2024-08-27	47,396	$2.92	2,449,082	No	4	M	Direct
Common Stock	Disposition	2024-08-27	389,356	$17.29	2,059,726	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock	Disposition	2024-08-26	64,405	$3.35	64,405	$3.35
Common Stock	Common Stock	Disposition	2024-08-26	55,000	$5.00	55,000	$5.00
Common Stock	Common Stock	Disposition	2024-08-26	16,984	$5.96	16,984	$5.96
Common Stock	Common Stock	Disposition	2024-08-26	40,500	$9.37	40,500	$9.37
Common Stock	Common Stock	Disposition	2024-08-26	60,000	$10.80	60,000	$10.80
Common Stock	Common Stock	Disposition	2024-08-27	341,960	$3.35	341,960	$3.35
Common Stock	Common Stock	Disposition	2024-08-27	47,396	$2.92	47,396	$2.92

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,082,980	2033-03-06	No	4	M	Direct
0	2027-02-14	No	4	M	Direct
0	2026-01-28	No	4	M	Direct
0	2025-10-09	No	4	M	Direct
0	2025-01-30	No	4	M	Direct
741,020	2033-03-06	No	4	M	Direct
0	2030-02-28	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,143,426	Indirect	See Footnote
Common Stock	580,957	Indirect	See Footnote

Footnotes

The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.50 to $18.45. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
The price reported in Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $17.25 to $17.375. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Includes, as of the transaction date, (i) 557,728 restricted stock units ("RSUs") granted on February 26, 2024, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 430,272 unvested RSUs granted on March 6, 2023 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 150,000 unvested RSUs granted on March 7, 2022 that will vest quarterly on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting;
(continued from footnote 3) (iv) 113,438 unvested time-based RSUs granted on September 29, 2021, subject to time-based vesting conditions which will vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (v) 45,788 unvested RSUs granted on February 25, 2021, which will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date, and will be settled into common stock upon vesting;
(continued from footnote 4) and (vi) 762,500 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
These shares are owned by Areth, LLC ("Areth"). The reporting person is a control person of Areth.
These shares are owned by Hariden, LLC ("Hariden"). The reporting person is the managing member of Hariden.
These options were granted on March 6, 2023 and vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 6, 2027.
These options were granted on February 14, 2017 and vested over four years with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 14, 2018, becoming fully vested on February 14, 2021.
These options were granted on January 28, 2016 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 28, 2020.
These options were granted on October 9, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on October 9, 2019.
These options were granted on January 30, 2015 and vested over four years with 25% vesting on the one year anniversary of the date of grant and the remaining 75% vesting monthly in equal installments over the next three years thereafter, becoming fully vested on January 30, 2019.
These options were granted on February 28, 2020 and vested over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024.
The Reporting Person is exercising these options due, in part, to their near-term expiration date.